請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/88276
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 吳政衞 | zh_TW |
dc.contributor.advisor | Cheng-Wei Wu | en |
dc.contributor.author | 吳翊綺 | zh_TW |
dc.contributor.author | Yi-Qi Goh | en |
dc.date.accessioned | 2023-08-09T16:19:43Z | - |
dc.date.available | 2023-11-09 | - |
dc.date.copyright | 2023-08-09 | - |
dc.date.issued | 2023 | - |
dc.date.submitted | 2023-07-21 | - |
dc.identifier.citation | Aitken, M., Kleinrock, M., & Pritchett, J. (2010). Global Oncology Trends 2022: Outlook to 2026.
Allen, J. W. (2001), Private Information and Spin-off Performance, Journal of Business, 74, 281-306. Danzon, P. M. (2014). Competition and Antitrust Issues in the Pharmaceutical Industry. DePamphilis, D. m. (2018). Mergers, Acquisitions, and Other Restructuring Activities. Elsevier Inc. Deshpande, A. D., Harris-hayes, M., & Schootman, M. (2008). Epidemiology of Diabetes and Diabetes-Related Complications. https://doi.org/10.2522/ptj.20080020 Duguleana, C., Duguleana, L., & Mirela Baba , C. et al. (2022). Recovery after Demerger: Evidence from Romanian Companies. Sustainability, 14(3). Ellery, T., & Hansen, N. (2012). Pharmaceutical Lifecycle Management: Making the Mos of Each and Every Brand. Wiley. Ghosh, S. k. (2014). Gaining Synergy by Spinning Off. GLOBSYN Management Journal, 2–5. Gyurjyan, G., Thaker, S., & Westhues, K. (2017). Rethinking Pharma Productivity. Handoo, S., Arora, V., & Khera, Deepak. et al. (2016). A Comprehensive Study on Regulatory Requirements for Development and Filing of Generic Drugs Globally. International Journal of Pharmaceutical Investigation, 2(3), 99–105. Hisey, T., Jacoby, R., & Heim, M. et al. (2019). The Role of Distributors in the US Healthcare Industry. 5. Hofstrand , D. (2022). Product Life Cycle. Ag Decision Maker. Kaplan, S., & Weisbach, M. (1992). The Success of Acquisitions: Evidence from Divestitures. Journal of Finance, 47, 107–138. Krishnaswami, S. and Subramaniam, V. (1999), Information Asymmetry, Valuation and the Corporate Spin-off Decision, Journal of Financial Economics, 53, 73-112. Lin, T. C. W. (2015). Reasonable Investor(s). 95 Boston University Law Review. Mcguire, J. l., Hasskarl, H., & Bode, G. (2007). Pharmaceuticals, General Survey. Wiley. New Kid on the Block? Insights on CBD in the Consumer Health Market. (2020). KPMG Whitepaper. Peruffo, E., Pirolo, L., & Nenni, M. E. (2014). Spin-off and Innovation in the Pharmaceutical Industry. International Journal of Engineering Business Management, 6(1). Sabaté, E. (2003). Adherence to Long-Term Therapies: Evidence for Action. Schuhmacher, A., Hinder, Markus, Boger, N. et al. (2023). The Significance of Blockbusters in the Pharmaceutical Industry. Nature Reviews Drug Discovery, 22, 178. Severinsen, J. W., & Gundersen , H. G. (2014). The Conglomerate Discount Phenomenon - A Valuation of Orkla ASA. Singh, R., Bhowal, A., & Bawari, V. (2009). Impact of Demerger on Shareholders’ Wealth. Enterprise Risk Management. https://doi.org/https://doi.org/10.5296/erm.v1i1.64 Thomas, D., Burns, J., & Audette, J. et al. (2015). Clinical Development Success Rates 2006-2015. Thomas, M. (2012). Winning the Battle for Consumer Healthcare: Science versus the Marketers in Consumer Healthcare. ATKearney, 12. Upadhyay, K. (2015). R&D Productivity and M&A in the Pharmaceutical and Biotech Industries. 李正民,(2001),企業從政與公司價值創造 — 以 AT & T 為例,國立中央大學財務管理研究所,碩士論文 林建邦 ,(2019),臺灣在生物相似性藥品的機會與挑戰, 生物技術開發中心 林婉婷,黃嘉惠,(2008),藥學雜誌 — 臺灣與美國非處方藥管理制度比較 張恭銘,(2017),大藥廠之藥品生命週期管理策略 — 以威爾鋼、犀利士與樂威壯為例,國立政治大學科技管理與智慧財產研究所,碩士論文 張偉明 ,(2008),企業分割之探討—華碩電腦,國立臺灣大學會計與管理決策組,碩士論文 厲盛,Heinemann, P. , Teofilov, M. et al. (2023),醫療企業剝離分拆的趨勢研判和價值塑造,羅蘭貝格 3M Announces Plans to Create Long Term Value Through Spin-Off of Health Care Business. (2022, July 26). 3M. https://news.3m.com/2022-07-26-3M-Announces-Plans-to-Create-Long-Term-Value-Through-Spin-Off-of-Health-Care-Business Al-Khalaf, L. (2023, February 19). Big Pharma Hears Ticking of the Patent Time Bomb. The Times. https://www.thetimes.co.uk/article/big-pharma-hears-ticking-of-the-patent-time-bomb-bgdphpnbq Allen, T. (2019, April 19). 3 Divestment Strategy Frameworks to Align Portfolios. Midaxo. https://www.midaxo.com/blog/3-divestment-strategy-frameworks-to-align-portfolios Bristol-Myers Squibb Announces Split-Off of Mead Johnson. (2009, November 16). FiercePharma. https://www.fiercebiotech.com/biotech/bristol-myers-squibb-announces-split-off-of-mead-johnson Buntz, B. (2022, March 30). Pharma’s Top 20 R&D Spenders in 2021. Drug Discovery and Development. https://www.drugdiscoverytrends.com/pharmas-top-20-rd-spenders-in-2021/ Cameron, I. (2023, June 13). Pfizer and GSK to Battle for Share of a New RSV Vaccine Market. BioPharmaReporter. https://www.biopharma-reporter.com/Article/2023/06/13/Pfizer-and-GSK-to-battle-for-share-of-new-RSV-vaccine-market Chang, K., Grass, K., & Haxer, J. (2023, January 31). M&A in Healthcare and Life Sciences: Why the Industry’s Wait-and-See Days Will End. Bain & Company. https://www.bain.com/insights/healthcare-life-sciences-m-and-a-report-2023/anda-by-the-numbers-2022-in-review Cornell, J. (2021, July 15). GlaxoSmithKline To Spin-Off Consumer Healthcare Business By Mid-2022. Forbes. https://www.forbes.com/sites/joecornell/2021/07/15/glaxosmithkline-to-spin-off-consumer-healthcare-business-by-mid-2022/?sh=35290afd72d0 Generic Drugs: Questions & Answers. (2021, March 16). U.S Food & Drug Administration. https://www.fda.gov/drugs/frequently-asked-questions-popular-topics/generic-drugs-questions-answers Global M&A by the Numbers: 2022 in Review. (2023, February 13). S&P Global. https://pages.marketintelligence.spglobal.com/rs/565-BDO-100/images/global-manda-by-the-numbers-2022-in-review Grogan, K. (2022, February 11). Ipsen To Exit Consumer Health And Focus On Specialty Pharma. SCRIP. https://scrip.pharmaintelligence.informa.com/SC145879/Ipsen-To-Exit-Consumer-Health-And-Focus-On-Specialty-Pharma Grover, N., & Raitano, L. (2022, July 18). GSK’s Consumer Arm Haleon Debuts with Lacklustre Valuation. Reuters. https://www.reuters.com/markets/europe/gsk-spins-off-haleon-biggest-european-listing-decade-2022-07-18/ GSK Completes Acquisition of Sierra Oncology. (2022, July 1). GSK. https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-sierra-oncology/ GSK: I’m Convinced by The Spin-off Plan. (2021, October 9). Seeking Alpha. https://seekingalpha.com/article/4459151-glaxosmithkline-convinced-by-spin-off-plan-valuationierra-oncology/ Haas, J. (2018, February 7). Gilead’s Biktarvy Approval Heightens HIV Competition With ViiV. SCRIP. https://scrip.pharmaintelligence.informa.com/SC100359/Gileads-Biktarvy-Approval-Heightens-HIV-Competition-With-ViiV Johnson & Johnson Takes Steps to Equitably Resolve All Current and Future Talc Claims. (2021, October 14). Johnson & Johnson. https://www.jnj.com/johnson-johnson-takes-steps-to-equitably-resolve-all-current-and-future-talc-claims Khemlani, A. (2023, May 5). J&J Consumer Brand Spinoff Kenvue Debuts on NYSE. Yahoo Finance. https://finance.yahoo.com/news/jj-consumer-brand-spinoff-kenvue-debuts-on-nyse-172309512.html Lyu, D., & Feely, J. (2022, August 12). Investors Flee Drug Giants as Zantac Cancer Trials Approach. Bloomberg. https://www.bloomberg.com/news/articles/2022-08-11/investors-flee-pharma-giants-as-zantac-cancer-trials-approach?leadSource=uverify%20wall Mandal, A. (2023, June 15). Drug Patents and Generic Pharmaceutical Drugs. Medical & Lifesciences. https://www.news-medical.net/health/Drug-Patents-and-Generics.aspxa-by-the-numbers-2022-in-review Novartis and GSK to Exchange Assets and Launch Joint Venture. (2014, April 22). BBC. https://www.bbc.com/news/business-27107416 Novartis Announces Intention to Separate Sandoz Business to Create a Standalone Company by Way of a 100% Spin-Off. (2022, August 25). Novartis. https://www.novartis.com/news/media-releases/novartis-announces-intention-separate-sandoz-business-create-standalone-company-way-100-spin Novartis to Sell Stake in Consumer Healthcare Joint Venture to GSK for USD13.0 Billion to Focus on Strategic Priorities. (2018, March 27). Novartis. https://www.novartis.com/news/media-releases/novartis-sell-stake-consumer-healthcare-joint-venture-gsk-usd130-billion-focus-strategic-priorities Phrma. (2015). Biopharmaceutical Research & Development: The Process Behind New Medicines. PhRMA. https://phrma.org/resource-center/Topics/Research-and-Development/Biopharmaceutical-Research-Development:-The-Process-Behind-New-Medicines Pierson, B. (2023, June 1). J&J Faces New Trial over Talc Cancer Claims, amid Settlement Push. Reuters. https://www.reuters.com/business/healthcare-pharmaceuticals/jj-faces-new-trial-over-talc-cancer-claims-amid-settlement-push-2023-05-31/ Ramachandran, J., Manikandan, K. s, & Pant, A. (2013, December). Why Conglomerates Thrive (Outside the U.S.). Harvard Business Review. https://hbr.org/2013/12/why-conglomerates-thrive-outside-the-us Sanofi Board Approves Demerger of Its Consumer Healthcare Business. (2023, May 10). The Economic Times. https://economictimes.indiatimes.com/markets/stocks/news/sanofi-board-approves-demerger-of-its-consumer-healthcare-business/articleshow/100129846.cms?from=mdr Senior, M. (2023, January 9). Fresh from the Biotech Pipeline: Fewer Approvals, but Biologics Gain Share. Nature. https://www.nature.com/articles/s41587-022-01630-6 Sunny, M. (2023, April 6). J&J Rises as $9 Bln Talc Lawsuit Settlement Eases Overhang on Unit Spinoff. Reuters. https://www.reuters.com/business/healthcare-pharmaceuticals/jj-rises-89-bln-talc-lawsuit-settlement-eases-overhang-consumer-unit-spinoff-2023-04-05/ Unilever Update, 17 January 2022. (2022, January 18). Unilever. https://www.unilever.com/news/press-and-media/press-releases/2022/unilever-update/ Unilever Update, 19 January 2022. (2022, January 19). Unilever. https://www.unilever.com/news/press-and-media/press-releases/2022/unilever-update-19-january-2022/ Update - GSK Consumer Healthcare. (2022, January 15). GSK. https://www.gsk.com/en-gb/media/press-releases/update-gsk-consumer-healthcare/ Ward, S. (2023, February 2). Spinoffs Are the New IPOs. Mornigstar. https://www.morningstar.ca/ca/news/231314/spinoffs-are-the-new-ipos.aspx WHO. (2022, October 1). Ageing and Health. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/ageing-and-health Wilmot, S. (2023, January 18). Bayer Could Go the Way of General Electric and Daimler. Wall Street Journal. https://www.wsj.com/articles/bayer-could-go-the-way-of-general-electric-and-daimler-11674037679 爽身粉的各種安全說明. (n.d.). 嬌生嬰兒. https://www.johnsonsbaby.com.tw/johnsons-baby-skin-care/johnsons-safety-standards/talc-safety 舒安居. (2020, January 4). 兩條腿走路:淺論新藥保護的兩個機制. 科技資訊室. https://iknow.stpi.narl.org.tw/Post/Read.aspx?PostID=13095 | - |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/88276 | - |
dc.description.abstract | 近年來,各大跨國公司紛紛開始瘦身,將非核心業務出售或分拆為獨立營運的新公司。各大公司開始思考旗下最賺錢的業務為何,他們必須緊緊抓住這些金雞母並灌溉其與大部分資金及注意力。而那些相較穩定卻沒有大幅進步空間的業務此時將會被分割出去,以使公司有限的資源可以被放置在最合適的地方。製藥產業亦躲不過這波“分拆潮”,許多大型製藥公司如輝瑞(Pfizer)、默克(Merck)、嬌生(Johnson & Johnson)等不是已經將部分事業體分拆,就是正在準備分拆的路上。
本研究通過分析目前最大型的消費保健品事業體分拆上市案:GSK – Haleon分拆及嬌生 – Kenvue分拆,探討二者分拆背後的考量因素及分拆後的績效。分拆動機將以四大面向既策略、營運、財務及法律面向進行分析及歸納,績效分析則從股價表現、企業價值倍數(EV/EBITDA)及本益比(P/E ratio)三個指標切入,藉此分析二者的分拆後績效表現。 本研究結果顯示二者在分拆後的獨立估值加總皆比分拆前表現佳,可見通過分拆可以減少企業綜合折讓(Conglomerate Discount),投資者願意給予分別獨立營運、財務透明度更高的公司更高的評價。但在GSK個案中投資者卻因對其所保留下的核心業務缺乏信心,導致GSK在分拆後的績效表現比被分拆事業體來得更差。而對於不管是製藥、醫療器材或消費保健品都為產業領導者的嬌生,則分拆後的績效十分亮眼。 | zh_TW |
dc.description.abstract | In recent years, we have seen several giant multinational corporations started to slim down, selling off non-core businesses or spinning them off into new, independently operating companies. Companies are starting to think about what their most profitable businesses are, and spend most their capital and attention on to these cash. Businesses that are relatively stable but do not offer much room for improvement will be spun off so that the company's limited resources can be invested in the most effective way. Big pharmas such as Pfizer, Merck, and Johnson & Johnson, have either spun off parts of their businesses or are on their way to do so.
Through analysis on the recent largest pharmaceutical spin-offs: GSK-Haleon and Johnson & Johnson (J&J) - Kenvue, this study aims to examine the factors behind these spin-offs and the post-spin-off performance. The motivations for the spin-offs were analyzed and summarized in terms of strategic, operational, financial, and legal aspects, while the post-spin performance analysis was based on three indicators: stock price performance, EV/EBITDA, and P/E ratio, in order to understand the motivations and performance of the two spin-offs. The results of this study show that the post-spin-off performance of both companies is higher than its pre-spin performance, indicating that the spin-off helps to reduce conglomerate discount and investors are willing to give higher valuations to the separately operated companies. However, in the case of GSK, investors’ lack of confidence in its retained core business, resulting in a poorer post-spin-off performance than the spun-off business. In contrast, in the case of J&J, which is the industry leader in pharmaceuticals, and excels at medical devices and consumer healthcare products, its performance after the spin-off was very impressive. | en |
dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2023-08-09T16:19:43Z No. of bitstreams: 0 | en |
dc.description.provenance | Made available in DSpace on 2023-08-09T16:19:43Z (GMT). No. of bitstreams: 0 | en |
dc.description.tableofcontents | 誌謝 i
摘要 ii Abstract iii 圖目錄 vii 表目錄 viii 第一章 緒論 1 第一節 研究背景與動機 1 第二節 研究目的 2 第三節 研究方法及流程 3 第二章 文獻回顧 4 第一節 企業分拆形式 4 2.1.1 Divestiture/ Sell-off 4 2.1.2 Spin-off 4 2.1.3 Split-up 4 2.1.4 Split-off 4 2.1.5 Equity Carve-out 5 第二節 企業分拆動機 5 2.2.1 聚焦核心業務 5 2.2.2 淘汰表現不佳之事業體 5 2.2.3 法規相關考量 5 2.2.4 事業體之間無法產生綜效 6 2.2.5 募集資金 6 2.2.6 降低風險 6 2.2.7 淘汰早前併購的事業體 6 2.2.8 提升企業經營透明度 7 2.2.9 績效表現 vs 策略適配度 7 第三章 產業分析 8 第一節 製藥產業介紹及發展沿革 8 3.1.1 製藥產業介紹 8 3.1.2 製藥產業發展沿革 9 3.1.3 現代製藥產業趨勢 10 3.1.4 產業特色 12 第二節 產業現況 17 第三節 製藥產業分析 20 3.3.1五力分析 20 3.3.2 商業模式九宮格分析 22 3.3.3 製藥業分拆浪潮 35 3.3.4 製藥產業的合併與分拆 41 第四章 個案公司分析 43 第一節 GSK - Haleon分拆個案 43 4.1.1公司簡介 43 4.1.2 分拆個案介紹 44 4.1.3 分拆動機 47 4.1.4 分拆形式 51 4.1.5分拆績效 52 第二節 嬌生 - Kenvue 分拆個案 58 4.2.1 公司簡介 58 4.2.2 分拆個案介紹 59 4.2.3 分拆動機 60 4.2.4 分拆形式 66 4.2.5 分拆績效 66 第五章 研究結論 72 第一節 研究結論 72 第二節 未來研究建議 74 參考文獻 75 | - |
dc.language.iso | zh_TW | - |
dc.title | 跨國藥廠消費保健品事業體分拆之策略分析:以葛蘭素史克及嬌生分拆案為例 | zh_TW |
dc.title | The Analysis of Global Pharmaceutical Companies’ Consumer Healthcare Divestment Strategy: Case Study of GSK and Johnson & Johnson | en |
dc.type | Thesis | - |
dc.date.schoolyear | 111-2 | - |
dc.description.degree | 碩士 | - |
dc.contributor.oralexamcommittee | 林舒柔;蘇威傑 | zh_TW |
dc.contributor.oralexamcommittee | Shu-Jou Lin;Wei-Chieh Su | en |
dc.subject.keyword | 製藥產業,專利藥,消費保健品,企業分拆,分拆動機,權益分割, | zh_TW |
dc.subject.keyword | Pharmaceutical industry,Patent drug,Consumer Healthcare,Spin-off,Spin-off motivation,Equity carve-out, | en |
dc.relation.page | 81 | - |
dc.identifier.doi | 10.6342/NTU202301797 | - |
dc.rights.note | 同意授權(限校園內公開) | - |
dc.date.accepted | 2023-07-24 | - |
dc.contributor.author-college | 管理學院 | - |
dc.contributor.author-dept | 國際企業學系 | - |
顯示於系所單位: | 國際企業學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-111-2.pdf 授權僅限NTU校內IP使用(校園外請利用VPN校外連線服務) | 2.97 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。